Keap1 inhibits Nrf2 activity when activated, exacerbating oxidative stress; thus, Keap1 inhibitors such as Ginsenoside reduce endothelial dysfunction and AS, and these findings illustrated that HO‐1 activators and Keap1 inhibitors may augment the atheroprotective effects of Nrf2.84 This evidence concerns the gene KEAP1 and endothelial dysfunction.